This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ellis, S. G. Articles by Topol, E. J. Search for Related Content PubMed PubMed Citation Articles by Ellis, S. G. Articles by Topol, E. J.

(Circulation. 1995;92:741-747.)
© 1995 American Heart Association, Inc.

Articles

In-Hospital Cost of Percutaneous Coronary Revascularization

Critical Determinants and Implications

Stephen G. Ellis, MD; Dave P. Miller, MS; Kimberly J. Brown, RN; Nowa Omoigui, MD; Georgiana L. Howell; Michael Kutner, PhD; Eric J. Topol, MD

From the Departments of Cardiology (S.G.E., K.J.B., N.O., G.L.H., J.G., E.J.T.) and Biostatistics (D.P.M., M.K.), The Cleveland Clinic Foundation, Cleveland, Ohio.

Correspondence to Stephen G. Ellis, MD, The Cleveland Clinic Foundation, 9500 Euclid Ave, F-25, Cleveland, OH 44195.

Background Hospital charges associated with percutaneous transluminal coronary revascularization (PTCR) in the United States exceeded $6 billion in 1994 and are likely to be constrained in some manner in the near future. Despite this high cost to the public, little is known about the major determinants and sources of variability of PTCR.

Methods and Results From a consecutive series of 1258 procedures with attempted PTCR at a single tertiary referral center, we analyzed 65 clinical, angiographic, physician, and outcome variables as potential correlates of total (hospital and physician) cost. Direct and indirect costs, both hospital and physician, were determined on the basis of resource utilization using "top-down" methodology and were available for 1237 procedures (1086 patients) (98.3%). Mean (±SD) patient age was 62±11 years, 76% were male, 3% had acute myocardial infarction, 71% had unstable angina, 58% had multivessel disease, left ventricular ejection fraction was 54±12%, 26% had use of at least one nonballoon revascularization device, and median length of stay was 4.4 days. Procedural success was obtained in 89%, and major complications (death, bypass surgery, or Q-wave myocardial infarction) occurred in 3.8%. The median cost was $9176, but it was asymmetrically distributed, and the interquartile and total ranges were wide ($7333 to $13 845 and $3422 to $193 474, respectively). Analyses of independent correlates of cost and log_e(cost) were performed using multivariate linear regression in training and test populations. Modeling found 15 independent preprocedural correlates of log_e(cost) (R²=.37) and 23 overall correlates (R²=.65), excluding length of stay per se. Addition of length of stay to the model increased the explanatory power of the model to R²=.82. Preprocedural variables most predictive of log_e(cost) included presentation with acute myocardial infarction, decision delay (>48 hours between admission and diagnostic angiography and/or >24 hours between angiography and intervention), weekend delay, use of intra-aortic balloon counterpulsation, intention to stent, creatinine 2.0 mg%, and lesion complexity (modified American College of Cardiology/American Heart Association score) (all P<.001). In the model that included postprocedural variables as well, length of stay, noncardiac death, urgent bypass surgery, use of the Rotablator, Q-wave myocardial infarction, rise in creatinine 1.0%, and blood product transfusion were all strong independent correlates of log_e(cost) (P<.001).

Conclusions The range of total hospital costs associated with percutaneous intervention is extraordinarily wide. Baseline patient characteristics account for nearly half of the explained variance, but procedural complications and system delays account for much of the remainder. Quantification of the determinants of cost may promote more economically efficient care in the future.

Key Words: angioplasty • coronary disease • cost analysis

This article has been cited by other articles:

				R. S. Watson, G. Clermont, J. P. Kinsella, L. Kong, R. E. Arendt, G. Cutter, W. T. Linde-Zwirble, S. H. Abman, D. C. Angus, and on behalf of the Prolonged Outcomes After Nitric O Clinical and Economic Effects of iNO in Premature Newborns With Respiratory Failure at 1 Year Pediatrics, November 1, 2009; 124(5): 1333 - 1343. [Abstract] [Full Text] [PDF]

				W. J. Kostis, K. Demissie, S. W. Marcella, Y.-H. Shao, A. C. Wilson, A. E. Moreyra, and the Myocardial Infarction Data Acquisition System Weekend versus Weekday Admission and Mortality from Myocardial Infarction N. Engl. J. Med., March 15, 2007; 356(11): 1099 - 1109. [Abstract] [Full Text] [PDF]

				D. C. Angus, W. T. Linde-Zwirble, S. W. Tam, J. K. Ghali, M. L. Sabolinski, V. G. Villagra, W. C. Winkelmayer, M. Worcel, and for the African-American Heart Failure Trial (A-He Cost-Effectiveness of Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine Therapy for Blacks With Heart Failure Circulation, December 13, 2005; 112(24): 3745 - 3753. [Abstract] [Full Text] [PDF]

				D. J. Cohen, A. M. Lincoff, T. A. Lavelle, H.-L. Chen, A. Bakhai, R. H. Berezin, D. Jackman, I. J. Sarembock, and E. J. Topol Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: Results from the REPLACE-2 trial J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1792 - 1800. [Abstract] [Full Text] [PDF]

				P. A. Cowper, E. D. Peterson, E. R. DeLong, M. B. Wightman, R. P. Wawrzynski, L. H. Muhlbaier, and M. H. Sketch Jr The impact of statistical adjustment on economic profiles of interventional cardiologists J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1416 - 1423. [Abstract] [Full Text] [PDF]

				K T Koch, J J Piek, M H Prins, R J de Winter, K Mulder, K I Lie, and J G P Tijssen Triage of patients for short term observation after elective coronary angioplasty Heart, May 1, 2000; 83(5): 557 - 563. [Abstract] [Full Text]

				A. Kastrati, A. Schomig, S. Elezi, J. Dirschinger, J. Mehilli, H. Schuhlen, R. Blasini, and F.-J. Neumann Prognostic Value of the Modified American College of Cardiology/American Heart Association Stenosis Morphology Classification for Long-Term Angiographic and Clinical Outcome After Coronary Stent Placement Circulation, September 21, 1999; 100(12): 1285 - 1290. [Abstract] [Full Text] [PDF]

				E. D. Peterson, P. A. Cowper, E. R. DeLong, J. P. Zidar, R. S. Stack, and D. B. Mark Acute and long-term cost implications of coronary stenting J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1610 - 1618. [Abstract] [Full Text] [PDF]

				S. G. Ellis, D. Miller, T. F. Keys, K. Brown, R. Ellert, G. Howell, A. M. Lincoff, and E. J. Topol Comparing physician-specific two-year patient outcomes after coronary angiography: Methodologic issues and results J. Am. Coll. Cardiol., April 1, 1999; 33(5): 1278 - 1285. [Abstract] [Full Text] [PDF]

				K T Koch, J J Piek, R J de Winter, K Mulder, C E Schotborgh, J G P Tijssen, and K I Lie Two hour ambulation after coronary angioplasty and stenting with 6 F guiding catheters and low dose heparin Heart, January 1, 1999; 81(1): 53 - 56. [Abstract] [Full Text]

				T. Mann, G. Cubeddu, J. Bowen, J. E. Schneider, M. Arrowood, W. N. Newman, M. J. Zellinger, and G. C. Rose Stenting in acute coronary syndromes: a comparison of radial versus femoral access sites J. Am. Coll. Cardiol., September 1, 1998; 32(3): 572 - 576. [Abstract] [Full Text] [PDF]

				DETERMINANTS OF COST OF PTCA Journal Watch (General), September 1, 1995; 1995(901): 7 - 7. [Full Text]